P
DGX icon

&Partners’s Quest Diagnostics DGX Stock Holding History

&Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24M Buy
122,183
+11,081
+10% +$2.15M 0.12% 163
2025
Q4 		$19.3M Buy
111,102
+10,088
+10% +$1.84M 0.1% 180
2025
Q3 		$19.3M Buy
101,014
+11,343
+13% +$2.01M 0.12% 156
2025
Q2 		$16.1M Buy
89,671
+64,095
+251% +$11.1M 0.12% 165
2025
Q1 		$4.28M Sell
25,576
-2,018
-7% -$332K 0.05% 328
2024
Q4 		$4.19M Buy
27,594
+15,938
+137% +$2.48M 0.05% 307
2024
Q3 		$1.81M Buy
11,656
+7,093
+155% +$1.06M 0.03% 383
2024
Q2 		$620K Buy
+4,563
New +$625K 0.03% 471

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

&Partners's DGX Position: Q1 2026 in Review

&Partners increased its Quest Diagnostics (DGX) stake by 10% in Q1 2026, buying an estimated $2.15M and bringing the position to 122,183 shares worth $24M. The position accounts for 0.12% of the portfolio, ranked #163.

&Partners first reported a position in DGX in Q2 2024 and has held it in 8 quarters since. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • &Partners held 122,183 shares of Quest Diagnostics worth $24M as of Q1 2026.
  • &Partners bought 11,081 Quest Diagnostics shares in Q1 2026, an estimated $2.15M.
  • Quest Diagnostics made up 0.12% of &Partners's portfolio in Q1 2026, its #163 holding.
  • &Partners first reported a position in Quest Diagnostics in Q2 2024 and has held it in 8 quarters since.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.